Does the media refer more to BEAM or NTLA?

In the previous week, Beam Therapeutics had 6 more articles in the media than Intellia Therapeutics. MarketBeat recorded 8 mentions for Beam Therapeutics and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.64 beat Beam Therapeutics' score of 0.33 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRSP or NTLA?

In the previous week, CRISPR Therapeutics had 5 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for CRISPR Therapeutics and 2 mentions for Intellia Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.65 beat Intellia Therapeutics' score of 0.64 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NTLA or EDIT?

In the previous week, Editas Medicine had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 3 mentions for Editas Medicine and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.64 beat Editas Medicine's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NTLA or LGND?

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 5 mentions for Ligand Pharmaceuticals and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.64 beat Ligand Pharmaceuticals' score of 0.32 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Intellia Therapeutics (NTLA) Competitors

$12.26 +0.14 (+1.16%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$12.33 +0.07 (+0.57%)

As of 10/2/2026 07:46 PM Eastern

Compare

NTLA vs. BEAM, CRSP, EDIT, LGND, and CGON

Should you buy Intellia Therapeutics stock or one of its competitors? Intellia Therapeutics's main competitors and comparable companies include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Ligand Pharmaceuticals (LGND), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Intellia Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	18.11	-$79.99M	-$0.86	N/A
Intellia Therapeutics	$67.67M	25.39	-$412.69M	-$3.36	N/A

Beam Therapeutics has a net margin of -54.75% compared to Intellia Therapeutics' net margin of -672.16%. Beam Therapeutics' return on equity of -30.71% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Beam Therapeutics has a beta of 2.2, suggesting that its share price is 120% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

In the previous week, Beam Therapeutics had 6 more articles in the media than Intellia Therapeutics. MarketBeat recorded 8 mentions for Beam Therapeutics and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.64 beat Beam Therapeutics' score of 0.33 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics presently has a consensus price target of $49.00, indicating a potential upside of 100.00%. Intellia Therapeutics has a consensus price target of $20.98, indicating a potential upside of 71.11%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Beam Therapeutics beats Intellia Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Intellia Therapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Intellia Therapeutics has a net margin of -672.16% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

In the previous week, CRISPR Therapeutics had 5 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for CRISPR Therapeutics and 2 mentions for Intellia Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.65 beat Intellia Therapeutics' score of 0.64 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

CRISPR Therapeutics presently has a consensus target price of $67.94, suggesting a potential upside of 22.57%. Intellia Therapeutics has a consensus target price of $20.98, suggesting a potential upside of 71.11%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Intellia Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,526.93	-$581.60M	-$4.76	N/A
Intellia Therapeutics	$67.67M	25.39	-$412.69M	-$3.36	N/A

Summary

Intellia Therapeutics beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Intellia Therapeutics compare to Editas Medicine?

Intellia Therapeutics (NASDAQ:NTLA) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Intellia Therapeutics currently has a consensus target price of $20.98, indicating a potential upside of 71.11%. Editas Medicine has a consensus target price of $5.80, indicating a potential upside of 121.37%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Editas Medicine has a net margin of -157.32% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Editas Medicine	-157.32%	-196.63%	-38.17%

In the previous week, Editas Medicine had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 3 mentions for Editas Medicine and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.64 beat Editas Medicine's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intellia Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Editas Medicine has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	25.39	-$412.69M	-$3.36	N/A
Editas Medicine	$40.52M	9.93	-$160.06M	-$0.75	N/A

Summary

Editas Medicine beats Intellia Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Intellia Therapeutics compare to Ligand Pharmaceuticals?

Intellia Therapeutics (NASDAQ:NTLA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Ligand Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	25.39	-$412.69M	-$3.36	N/A
Ligand Pharmaceuticals	$268.09M	22.53	$124.45M	$9.35	32.40

Intellia Therapeutics presently has a consensus target price of $20.98, suggesting a potential upside of 71.11%. Ligand Pharmaceuticals has a consensus target price of $337.89, suggesting a potential upside of 11.53%. Given Intellia Therapeutics' higher probable upside, equities analysts plainly believe Intellia Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 5 mentions for Ligand Pharmaceuticals and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.64 beat Ligand Pharmaceuticals' score of 0.32 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ligand Pharmaceuticals has a net margin of 67.88% compared to Intellia Therapeutics' net margin of -672.16%. Ligand Pharmaceuticals' return on equity of 20.06% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Intellia Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats Intellia Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to CG Oncology?

Intellia Therapeutics (NASDAQ:NTLA) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Intellia Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

In the previous week, Intellia Therapeutics had 2 more articles in the media than CG Oncology. MarketBeat recorded 2 mentions for Intellia Therapeutics and 0 mentions for CG Oncology. Intellia Therapeutics' average media sentiment score of 0.64 beat CG Oncology's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Intellia Therapeutics	Positive
CG Oncology	Neutral

Intellia Therapeutics has a net margin of -672.16% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
CG Oncology	-3,602.68%	-25.20%	-23.98%

CG Oncology has lower revenue, but higher earnings than Intellia Therapeutics. CG Oncology is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	25.39	-$412.69M	-$3.36	N/A
CG Oncology	$4.04M	1,478.36	-$160.99M	-$2.69	N/A

Intellia Therapeutics currently has a consensus price target of $20.98, suggesting a potential upside of 71.11%. CG Oncology has a consensus price target of $87.78, suggesting a potential upside of 30.27%. Given Intellia Therapeutics' higher possible upside, equities analysts clearly believe Intellia Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Intellia Therapeutics beats CG Oncology on 10 of the 17 factors compared between the two stocks.

Get Intellia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTLA vs. The Competition

Export

Metric	Intellia Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.72B	$3.86B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-3.65	13.06	275.67	26.04
Price / Sales	25.39	1,292.17	656.66	111.05
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	2.11	16.63	10.93	6.31
Net Income	-$412.69M	-$22.71M	$3.51B	$362.16M
7 Day Performance	4.34%	-2.99%	-2.00%	-1.66%
1 Month Performance	-3.77%	-10.81%	-6.19%	-4.68%
1 Year Performance	-38.58%	19.19%	8.03%	1.57%

Intellia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTLA Intellia Therapeutics	2.6087 of 5 stars	$12.26 +1.2%	$20.98 +71.1%	-38.6%	$1.72B	$67.67M	N/A	377	Gap Up
BEAM Beam Therapeutics	2.5907 of 5 stars	$24.23 -0.2%	$49.00 +102.2%	-4.9%	$2.50B	$139.74M	N/A	540	Analyst Upgrade
CRSP CRISPR Therapeutics	2.6241 of 5 stars	$54.09 -0.3%	$67.94 +25.6%	-18.2%	$5.23B	$3.51M	N/A	393
EDIT Editas Medicine	1.7472 of 5 stars	$2.51 -2.7%	$5.80 +131.1%	-33.2%	$385.49M	$40.52M	N/A	87
LGND Ligand Pharmaceuticals	3.4591 of 5 stars	$314.10 +4.2%	$337.89 +7.6%	+67.4%	$6.26B	$268.09M	33.59	47

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTLA) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, LGND, and CGON

How does Intellia Therapeutics compare to Beam Therapeutics?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Summary

How does Intellia Therapeutics compare to Ligand Pharmaceuticals?

Summary

How does Intellia Therapeutics compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, LGND, and CGON

How does Intellia Therapeutics compare to Beam Therapeutics?

Which has better valuation and earnings, BEAM or NTLA?

Is BEAM or NTLA more profitable?

Which has more risk and volatility, BEAM or NTLA?

Does the media refer more to BEAM or NTLA?

Do analysts prefer BEAM or NTLA?

Do insiders & institutionals believe in BEAM or NTLA?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Is CRSP or NTLA more profitable?

Does the media refer more to CRSP or NTLA?

Which has more risk and volatility, CRSP or NTLA?

Do analysts rate CRSP or NTLA?

Do insiders and institutionals hold more shares of CRSP or NTLA?

Which has better earnings and valuation, CRSP or NTLA?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Do institutionals and insiders believe in NTLA or EDIT?

Do analysts prefer NTLA or EDIT?

Is NTLA or EDIT more profitable?

Does the media prefer NTLA or EDIT?

Which has more risk and volatility, NTLA or EDIT?

Which has stronger earnings and valuation, NTLA or EDIT?

Summary

How does Intellia Therapeutics compare to Ligand Pharmaceuticals?

Which has higher earnings and valuation, NTLA or LGND?

Do analysts prefer NTLA or LGND?

Does the media prefer NTLA or LGND?

Is NTLA or LGND more profitable?

Do institutionals & insiders have more ownership in NTLA or LGND?

Which has more risk & volatility, NTLA or LGND?

Summary

How does Intellia Therapeutics compare to CG Oncology?

Which has more risk and volatility, NTLA or CGON?

Does the media prefer NTLA or CGON?

Is NTLA or CGON more profitable?

Which has preferable valuation and earnings, NTLA or CGON?

Do analysts rate NTLA or CGON?

Do institutionals and insiders have more ownership in NTLA or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools